Background
Malinda Gibbons received a Tdap vaccine on April 19, 2016. Approximately one month later, she developed widespread tingling, vertigo, difficulty walking, and severely impaired eye movement. After testing positive for GQ1b antibodies, she was diagnosed with Guillain-Barré Syndrome-Miller Fisher Variant and treated with intravenous immunoglobulin. By July and August 2016, her double vision, ptosis, and eye weakness had resolved, and she reported feeling near normal except when overheated.
Gibbons petitioned for compensation under the National Childhood Vaccine Injury Act, alleging that the vaccine caused her condition. Special Master Christian J. Moran denied compensation because she had not proved that residual effects or complications persisted for more than six months after vaccination, as required by the Act. On review, Gibbons argued that gum tingling, leg and toe cramps, and heat sensitivity were continuing manifestations of her GBS-MFV and that the special master improperly discounted her experts, treating physicians, and supporting literature.
The Court’s Holding
The Court of Federal Claims denied Gibbons’s petition for review and sustained the special master’s decision. Applying the highly deferential arbitrary-and-capricious standard to the special master’s factual findings, the court concluded that he had considered the relevant evidence, drawn plausible inferences, and articulated rational grounds for finding that Gibbons failed to prove qualifying residual effects lasting more than six months.
The court upheld the special master’s evaluation of the disputed symptoms and competing expert opinions. The record permitted him to find that later gum tingling was intermittent and not persuasively linked to incompletely healed nerves; that leg and toe cramps were not documented until years after the acute illness; and that the evidence did not establish heat sensitivity as a continuing neurologic effect of GBS-MFV. Because Gibbons failed to establish the statutory severity element of her prima facie case, the burden never shifted to the government to prove that her later symptoms resulted from unrelated factors.
Key Takeaways
- A Vaccine Act petitioner relying on residual effects must prove by a preponderance of the evidence that vaccine-related effects or complications continued for more than six months.
- A reviewing court does not reweigh medical records, credibility determinations, or competing expert testimony when the special master’s findings have a rational basis in the record.
- The government’s burden to establish an unrelated cause arises only after the petitioner proves every element of a prima facie claim, including statutory severity.
Why It Matters
The decision underscores that diagnosis and causation alone do not establish eligibility for Vaccine Act compensation. Petitioners must separately prove the required degree and duration of injury, with medical records or persuasive opinion evidence connecting later symptoms to the vaccine-related condition.
It also illustrates the difficulty of overturning a special master’s evidence-based severity determination. Conflicting testimony, sporadic symptoms, lengthy gaps in documentation, and plausible alternative explanations may support denial even when the petitioner experienced a serious acute neurologic illness.